Startups
Developing biologics for medical conditions where there has been no approved or satisfactory therapy.
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Life Sciences Partners | lspvc.com |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Rainier Therapeutics Announces Vofatamab FIERCE-22 Data Accepted for Presentation at ESMO 2019 Annual Congress | – Updated Interim Analysis from FIERCE-22 Phase 2 Trial in Metastatic Bladder Cancer- SEATTLE, WA and SAN LEANDRO, CA, July 29, 2019—Rainier Therapeutics, Inc., a privately held clinical stage drug development company, today announced that... | |
| Rainier Therapeutics Presents Data on Vofatamab in Patients with Advanced Urothelial Cell Carcinoma (Bladder Cancer) Previously Treated with Chemotherapy at ASCO GU 2019 | – Preliminary data from FIERCE-21 Phase 2 trial highlighted in oral presentation supports advancement to pivotal study – – Single agent activity and long-term treatment duration demonstrated– SAN LEANDRO, Calif., February 15, 2019—Rainier... | |
| Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer) | -Targeted antibody elicits responses in both FGFR3 wild-type and mutant/fusion patients- -Favorable tolerability and safety profile and prolonged treatment duration- – Results presented at America Society of Oncology (ASCO) Annual Meeting... | |
| Rainier Therapeutics Announces Appointment of Gary Christianson as Chief Technical Officer | SAN LEANDRO, Calif., May 1, 2019—Rainier Therapeutics, Inc., a privately held clinical stage drug development company, today announced the appointment of Gary Christianson, PE, as Chief Technical Officer. Mr. Christianson brings more than ... | |
| BioClin Therapeutics Announces Name Change to Rainier Therapeutics | SAN LEANDRO, Calif., November 27 2018— BioClin Therapeutics, Inc., a privately-held clinical stage drug development company focused on helping patients in the high unmet need of bladder cancer, today announced the company is changing its na... | |
| Rainier Therapeutics Announces Vofatamab Data Accepted for Presentation at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting | -FIERCE-21 and FIERCE-22 Phase 2 Trials in Metastatic Bladder Cancer SAN LEANDRO, Calif., April 25, 2019—Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced that abstracts related to trials... |